1. Pink Sheet

Pacira's Exparel: US FDA Panel Narrowly Rejects Nerve Block Claim

 
• By Sue Sutter

Inconsistent efficacy data and safety concerns about falls and systemic toxicity lead to advisory committee vote against a labeling expansion for the local anesthetic; Pacira's proposed revisions to the drug's existing infiltration claim also meet some resistance.

FDA entrance sign 2016

Citing efficacy as well as safety concerns, a US FDA advisory committee narrowly recommended against the addition of a nerve block indication to the labeling ofPacira Pharmaceuticals Inc.'s local anesthetic Exparel (bupivacaine liposome injectable suspension).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers